Literature DB >> 8635122

Postoperative hepatitis status as a significant risk factor for recurrence in cirrhotic patients with small hepatocellular carcinoma.

K Shirabe1, K Takenaka, A Taketomi, N Kawahara, K Yamamoto, M Shimada, K Sugimachi.   

Abstract

BACKGROUND: Recurrence of small hepatocellular carcinoma (HCC) is common. Recent studies have suggested that the status of the underlying liver parenchyma is a significant risk factor for recurrence of HCC.
METHODS: The postoperative values of transaminase were examined every 6 months after surgery in 57 patients with a surgically resected solitary small HCC measuring up to 3 cm in greatest dimension. Based on the patterns of the transaminase values, the patients were divided into two groups. Group 1 (n = 20) had a high transaminase level; the values of postoperative transaminase were always more than 100 IU/L. Group II (n = 37) had a low transaminase level; the values of postoperative transaminase were sometimes lower than 100 IU/L.
RESULTS: The cumulative carcinoma-free survival rates in Groups I and II were 91% and 80%, respectively, at 1 year, 64.5% and 5.5%, respectively, at 3 years, and 48.2% and 0%, respectively, at 5 years after surgery. The disease free survival rates in Group I were significantly lower than those in Group II (P = 0.0007), although no significant differences in histologic risk factors for recurrence or in clinical backgrounds were observed. With regard to the recurrence pattern, solitary recurrence was more frequently observed in Group I (P = 0.02), compared with the patients in Group II. A histologic comparison between the primary and recurrent tumor in patients who underwent re-resection for solitary recurrence demonstrated the possible multicentric occurrence of HCC in 2 of 8 patients (25%) in Group I.
CONCLUSIONS: This study suggests that the hepatitis status of the remnant liver plays an important role in the recurrence rates and patterns of small HCC after hepatectomy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635122

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  18 in total

1.  Prevention of cancer recurrence after treatment for hepatitis C virus-related hepatocellular carcinoma by interferon therapy.

Authors:  Shoji Kubo
Journal:  Clin J Gastroenterol       Date:  2009-04-08

2.  Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence.

Authors:  Giorgio Ercolani; Gian Luca Grazi; Matteo Ravaioli; Massimo Del Gaudio; Andrea Gardini; Matteo Cescon; Giovanni Varotti; Francesco Cetta; Antonino Cavallari
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

3.  Expression of hepatocyte growth factor activator inhibitor type 1 in human hepatocellular carcinoma and postoperative outcomes.

Authors:  Mayumi Funagayama; Kazuhiro Kondo; Kazuo Chijiiwa; Hiroaki Kataoka
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

4.  Improved long-term survival after liver resection for hepatocellular carcinoma in the modern era: retrospective study from HCV-endemic areas.

Authors:  Atsushi Sasaki; Yukio Iwashita; Kohei Shibata; Toshifumi Matsumoto; Masayuki Ohta; Seigo Kitano
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

5.  Prognostic factors after repeat hepatectomy for recurrent hepatocellular carcinoma.

Authors:  M Shimada; K Takenaka; K Taguchi; Y Fujiwara; T Gion; K Kajiyama; T Maeda; K Shirabe; K Yanaga; K Sugimachi
Journal:  Ann Surg       Date:  1998-01       Impact factor: 12.969

6.  Improvement of long-term outcomes in hepatitis C virus antibody-positive patients with hepatocellular carcinoma after hepatectomy in the modern era.

Authors:  Ken Shirabe; Kazuki Takeishi; Akinobu Taketomi; Hideaki Uchiyama; Hiroto Kayashima; Yoshihiko Maehara
Journal:  World J Surg       Date:  2011-05       Impact factor: 3.352

7.  Prognostic effects of causative virus in hepatocellular carcinoma according to the Japan integrated staging (JIS) score.

Authors:  Shoji Kubo; Hiromu Tanaka; Taichi Shuto; Shigekazu Takemura; Takatsugu Yamamoto; Takahiro Uenishi; Shogo Tanaka; Seikan Hai; Satoshi Yamamoto; Tsuyoshi Ichikawa; Shintaro Kodai; Kazuhiro Hirohashi
Journal:  J Gastroenterol       Date:  2005-10       Impact factor: 7.527

8.  A novel biomarker TERTmRNA is applicable for early detection of hepatoma.

Authors:  Norimasa Miura; Yukio Osaki; Miki Nagashima; Michimori Kohno; Kensho Yorozu; Kohei Shomori; Takamasa Kanbe; Kenji Oyama; Yukihiro Kishimoto; Shigeo Maruyama; Eijiro Noma; Yutaka Horie; Masatoshi Kudo; Seigo Sakaguchi; Yasuaki Hirooka; Hisao Ito; Hironaka Kawasaki; Junichi Hasegawa; Goshi Shiota
Journal:  BMC Gastroenterol       Date:  2010-05-18       Impact factor: 3.067

9.  Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation.

Authors:  Charles H Cha; Leyo Ruo; Yuman Fong; William R Jarnagin; Jinru Shia; Leslie H Blumgart; Ronald P DeMatteo
Journal:  Ann Surg       Date:  2003-09       Impact factor: 12.969

10.  Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C.

Authors:  Shoji Kubo; Shigekazu Takemura; Takahiro Uenishi; Takatsugu Yamamoto; Kazuki Ohba; Masao Ogawa; Seikan Hai; Tsuyoshi Ichikawa; Shintaro Kodai; Hiroji Shinkawa; Hiromu Tanaka
Journal:  World J Surg       Date:  2008-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.